MorphoSys AG
XETRA:MOR
MorphoSys AG
Cost of Revenue
MorphoSys AG
Cost of Revenue Peer Comparison
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
MorphoSys AG
XETRA:MOR
|
Cost of Revenue
-€32.8m
|
CAGR 3-Years
-44%
|
CAGR 5-Years
-37%
|
CAGR 10-Years
N/A
|
|
BioNTech SE
NASDAQ:BNTX
|
Cost of Revenue
-€599.8m
|
CAGR 3-Years
-117%
|
CAGR 5-Years
-112%
|
CAGR 10-Years
N/A
|
|
CureVac NV
NASDAQ:CVAC
|
Cost of Revenue
-€116.3m
|
CAGR 3-Years
-102%
|
CAGR 5-Years
-46%
|
CAGR 10-Years
N/A
|
|
Immatics NV
NASDAQ:IMTX
|
Cost of Revenue
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Biotest AG
XETRA:BIO
|
Cost of Revenue
-€404.3m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-3%
|
|
Formycon AG
XETRA:FYB
|
Cost of Revenue
-€54.8m
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
N/A
|
See Also
What is MorphoSys AG's Cost of Revenue?
Cost of Revenue
-32.8m
EUR
Based on the financial report for Mar 31, 2024, MorphoSys AG's Cost of Revenue amounts to -32.8m EUR.
What is MorphoSys AG's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-37%
Over the last year, the Cost of Revenue growth was 47%. The average annual Cost of Revenue growth rates for MorphoSys AG have been -44% over the past three years , -37% over the past five years .